IXICO plc IXICO secures new contract for GBP3.4 million (7387J)
24 Diciembre 2020 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 7387J
IXICO plc
24 December 2020
IXICO plc
("IXICO" or the "Company")
IXICO secures new contract for GBP3.4 million
IXICO broadens its rare disease franchise into SCA3, a rare
neurodegenerative condition
IXICO plc (AIM: IXI), the AI data analytics company delivering
insights in neuroscience, announces it has been awarded a GBP3.4
million contract to run over c.4.5 years by an existing client for
a Spinocerebellar Ataxia type 3 (SCA3) trial. SCA3 , also known as
Machado-Joseph disease, is a rare, neurodegenerative condition
resulting in movement disorders, rigidity, muscular atrophy and
paralysis. Currently there is no treatment to slow down or reverse
the progressive course of this terminal disease.
For the study, IXICO will provide operational services and
advanced AI neuroimaging solutions for volumetric, diffusion and
functional magnetic resonance imaging (vMRI, dMRI, rs-fMRI) as well
as magnetic resonance spectroscopy (H-MRS) and quantitative
susceptibility mapping (QSM). Having singularly focused on
neurological disorders since its inception, IXICO has a long and
established track record of enabling biopharmaceutical sponsors to
realise the full power of neuroimaging in CNS and rare disease
clinical trials.
Lammert Albers, Chief Commercial Officer of IXICO,
commented:
"SCA3 is an area with clear, unmet medical needs and we are
delighted to be chosen as the neuroimaging partner in this
spinocerebellar ataxia trial . Neuroimaging, with its unique
ability to reveal extraordinary information about the structural
and functional characteristics of the human brain is a powerful
tool in CNS studies, and we are proud to support our clients in
potentially unlocking new insights into disease progression ."
This contract was included in management's expectations of
performance for the current financial year and adds to the
Company's strong order book, providing further future revenue
visibility.
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales
Walbrook PR Ltd +44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTFEDFMDESSEDE
(END) Dow Jones Newswires
December 24, 2020 02:00 ET (07:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024